Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Status:
Active, not recruiting
Trial end date:
2021-11-30
Target enrollment:
Participant gender:
Summary
This pilot phase I trial studies the side effects of engineered donor stem cell transplant in
treating patients with hematologic malignancies. Sometimes the transplanted cells from a
donor can make an immune response against the body's normal cells (called graft-versus-host
disease). Using T cells specially selected from donor blood in the laboratory for transplant
may stop this from happening.